Zimmer Biomet (NYSE: ZBH) announced today that it received FDA 510(k) clearance for its Persona Revision SoluTion Femur.

Zimmer Biomet Holdings ... office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and ...

Zimmer Biomet’s flagship robot, Rosa, is expected to make gains in the near future, CEO Ivan Tornos said at the Barclays 27th Annual Global Healthcare Conference. Mr. Tornos said adoption of the robot ...

The Terminator actor teamed up with Zimmer Biomet to raise awareness about osteoarthritis, which affects more than 25 million ...

March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings ... clearance of Persona® Revision SoluTion™ Femur, a revision knee implant component offering an alternative for patients with ...

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Zimmer Biomet Holdings (ZBH – Research Report).

Zimmer Biomet Holdings ... with its orthopedics division contributing around $2.3 billion. Its knee and hip implant segments saw underlying growth rates of 1.3% and 4%, respectively, over 2023.

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Zimmer Biomet's new revision knee implant component ...

A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ...